Novotech Partners with Wonju Severance Christian Hospital to Drive Clinical Research Excellence in Korea
Novotech, a global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics at every phase, has signed a Memorandum of Understanding (MOU) with Wonju Severance Christian Hospital. The partnership between Wonju Severance Christian Hospital, located in Gangwon province of South Korea and Novotech marks the beginning of a new strategic collaboration focused on enhancing clinical research and medical innovation.
The partnership brings together Novotech’s global expertise in clinical trial management and Wonju Severance Christian Hospital’s outstanding research capabilities. The two organizations aim to enhance the quality of clinical trials and contributing to the development of cutting-edge therapeutics and improving patient care in the region.
At the signing ceremony, Prof. Young Uh, President of Wonju Severance Christian Hospital, emphasized the importance of the partnership, stating, “I am pleased to establish our first official partnership agreement with a globally reputable CRO like Novotech. Our hospital, the largest hospital-beds in the Gangwon region of South Korea provides great infrastructure of medical care, attracting patients from across the region. We are excited to work together with Novotech to further elevate our research and clinical services.” said Prof. Uh.
Dr. Yooni Kim, Managing Director Asia-Pacific at Novotech, highlighted the importance of strong collaboration in clinical research. “Collaboration with outstanding investigators is vital to the success of clinical trials. We look forward to working with the talented research team at Wonju Severance Christian Hospital to drive global clinical trials. We also hope this partnership will help extend clinical trial opportunities to a good-quality hospital beyond Seoul to other regions, contributing positively to local communities for patients.”
Through the strategic alliance, Novotech and Wonju Severance Christian Hospital aim to set new leverage their combined expertise to set new standards in clinical trials and medical services. The partnership will foster innovation and support Korea’s aspiration to lead the globalization of its medical industry.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218415353/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Life-saving Technologies at EuroELSO 2025: Eurosets Presents Landing Breathe and Xtreme Rescue28.4.2025 13:16:00 CEST | Press release
Eurosets, a cutting-edge Italian company specializing in the design of life-saving medical devices, unveils two crucial innovations at the EuroELSO 2025 congress: Landing Breathe and Xtreme Rescue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428669720/en/ Ettore Sansavini, GVM Care & Research President, and Antonio Petralia, CEO and Executive Vice President of Eurosets, with Xtreme Rescue and Jetson One Landing Breathe is a next-generation capnometer designed to provide comprehensive monitoring of both the mechanical oxygenator lung and the native lung during ECMO (extracorporeal membrane oxygenation) treatments. The device integrates with Landing Advance, which already analyzes 22 metabolic parameters. Thanks to this technology, clinicians can rely on a real-time, full picture of the patient’s respiratory condition, optimizing therapeutic management. Alongside this innovation, Eurosets also presents Xtreme Rescue, a p
Quantum Computing’s Rapid Rise Is a Risk to Cybersecurity and Business Stability – but Organisations Are Unprepared28.4.2025 13:00:00 CEST | Press release
Over two thirds (67%) of European IT professionals are worried that quantum computing could increase or shift cybersecurity risksYet only 4% say that their organisation has a defined quantum computing strategyOnly 35% believe that the timeline for quantum computing to enter the mainstream is a matter of years, not decades Quantum computing has revolutionary potential; expected to change life as we know it – and is broadly welcomed by 56% of cyber and IT professionals as creating opportunities for business. That’s according to new research from ISACA, the leading global professional association helping individuals and organisations in their pursuit of digital trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428853346/en/ ISACA’s 2025 Quantum Computing Pulse Poll features of-the-moment insights from 2,685 global professionals who work in digital trust fields, including cybersecurity, audit, risk or data privacy. This i
FPT Recognized in The Digital Transformation Services Landscape Report28.4.2025 12:06:00 CEST | Press release
Global IT firm FPT announced its inclusion in Forrester’s The Digital Transformation Services Landscape, Q2 2025. The report provides an overview of 35 digital transformation service providers and offers valuable insights into the current market dynamics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428400623/en/ FPT is recognized as a Notable Provider in the report which stated that transformation leaders can use digital transformation services to “articulate and orchestrate strategy-aligned transformation journeys; align tech modernization with people, organization, and culture change, and navigate transformation risks.” The report notes FPT's geographical focus in North America and Asia-Pacific, along with its industry focus in financial services, IT/Tech services, and manufacturing/production of industrial products. FPT’s suite of digital transformation services includes cutting-edge solutions in AI, cloud computing
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom